NeuroPace Statistics
Total Valuation
NeuroPace has a market cap or net worth of $546.25 million. The enterprise value is $557.41 million.
Important Dates
The last earnings date was Tuesday, November 4, 2025, after market close.
| Earnings Date | Nov 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NeuroPace has 33.31 million shares outstanding. The number of shares has increased by 12.36% in one year.
| Current Share Class | 33.31M |
| Shares Outstanding | 33.31M |
| Shares Change (YoY) | +12.36% |
| Shares Change (QoQ) | +0.83% |
| Owned by Insiders (%) | 3.64% |
| Owned by Institutions (%) | 62.65% |
| Float | 22.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.51 |
| Forward PS | 5.53 |
| PB Ratio | 29.47 |
| P/TBV Ratio | 29.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.88 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.86, with a Debt / Equity ratio of 3.84.
| Current Ratio | 4.86 |
| Quick Ratio | 3.82 |
| Debt / Equity | 3.84 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.26 |
Financial Efficiency
Return on equity (ROE) is -169.27% and return on invested capital (ROIC) is -13.17%.
| Return on Equity (ROE) | -169.27% |
| Return on Assets (ROA) | -11.19% |
| Return on Invested Capital (ROIC) | -13.17% |
| Return on Capital Employed (ROCE) | -20.79% |
| Revenue Per Employee | $515,565 |
| Profits Per Employee | -$130,359 |
| Employee Count | 184 |
| Asset Turnover | 0.93 |
| Inventory Turnover | 1.46 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +46.56% in the last 52 weeks. The beta is 1.85, so NeuroPace's price volatility has been higher than the market average.
| Beta (5Y) | 1.85 |
| 52-Week Price Change | +46.56% |
| 50-Day Moving Average | 12.26 |
| 200-Day Moving Average | 11.41 |
| Relative Strength Index (RSI) | 66.95 |
| Average Volume (20 Days) | 246,616 |
Short Selling Information
The latest short interest is 992,733, so 2.98% of the outstanding shares have been sold short.
| Short Interest | 992,733 |
| Short Previous Month | 957,773 |
| Short % of Shares Out | 2.98% |
| Short % of Float | 4.49% |
| Short Ratio (days to cover) | 4.68 |
Income Statement
In the last 12 months, NeuroPace had revenue of $94.86 million and -$23.99 million in losses. Loss per share was -$0.75.
| Revenue | 94.86M |
| Gross Profit | 72.83M |
| Operating Income | -18.22M |
| Pretax Income | -23.99M |
| Net Income | -23.99M |
| EBITDA | -18.02M |
| EBIT | -18.22M |
| Loss Per Share | -$0.75 |
Full Income StatementBalance Sheet
The company has $60.01 million in cash and $71.18 million in debt, giving a net cash position of -$11.17 million or -$0.34 per share.
| Cash & Cash Equivalents | 60.01M |
| Total Debt | 71.18M |
| Net Cash | -11.17M |
| Net Cash Per Share | -$0.34 |
| Equity (Book Value) | 18.52M |
| Book Value Per Share | 0.56 |
| Working Capital | 75.72M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$16.31 million and capital expenditures -$274,000, giving a free cash flow of -$16.58 million.
| Operating Cash Flow | -16.31M |
| Capital Expenditures | -274,000 |
| Free Cash Flow | -16.58M |
| FCF Per Share | -$0.50 |
Full Cash Flow StatementMargins
Gross margin is 76.77%, with operating and profit margins of -19.21% and -25.28%.
| Gross Margin | 76.77% |
| Operating Margin | -19.21% |
| Pretax Margin | -25.28% |
| Profit Margin | -25.28% |
| EBITDA Margin | -18.99% |
| EBIT Margin | -19.21% |
| FCF Margin | n/a |
Dividends & Yields
NeuroPace does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.36% |
| Shareholder Yield | -12.36% |
| Earnings Yield | -4.39% |
| FCF Yield | -3.04% |
Analyst Forecast
The average price target for NeuroPace is $17.00, which is 3.66% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.00 |
| Price Target Difference | 3.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 18.22% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NeuroPace has an Altman Z-Score of -3.71 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.71 |
| Piotroski F-Score | 4 |